HOP-1 Inhibitors
HOP-1 inhibitors vary widely in their targets, yet collectively they offer a comprehensive approach for modulating the activity of HOP-1 protein. BMS-777607 and LY294002 act on the PI3K/AKT pathway; when inhibited, these chemicals lead to reduced activity of HOP-1, which is regulated by this pathway. Similarly, SP600125 and AG490 target the JNK and JAK-STAT pathways, respectively. HOP-1 is known to interact with components of both these pathways, and its functional contribution is reduced when these pathways are blocked. IWR-1 and CHIR99021 have more specialized roles, targeting the Wnt and GSK-3β pathways, respectively. These inhibitors either degrade or accumulate β-catenin, thereby affecting HOP-1, a downstream effector of β-catenin.
PD98059 and ZM336372 focus on the MAPK pathway but target different components: MEK and RAF kinase, respectively. HOP-1 is indirectly regulated by the MAPK pathway via its interaction with other proteins, making these inhibitors effective in attenuating its function. Roscovitine acts as a CDK inhibitor, affecting the cell cycle where HOP-1 is implicated, thereby dampening its function. SB431542 disrupts the TGF-β pathway by inhibiting Smad2/3 phosphorylation; given that HOP-1 is known to interact with Smad proteins, this leads to reduced HOP-1 activity. Lastly, PP2 and Genistein inhibit Src kinase and multiple tyrosine kinases, respectively. These inhibitors are vital as HOP-1 is influenced by Src and is a component of pathways like JNK and MAPK that Genistein affects.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BMS 777607 | 1025720-94-8 | sc-364438 sc-364438A | 10 mg 50 mg | $392.00 $1244.00 | 1 | |
MET kinase inhibitor that attenuates the PI3K/AKT pathway. HOP-1 is regulated by the PI3K/AKT pathway, causing decreased HOP-1 activity when the pathway is inhibited. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that blocks JNK pathway. HOP-1 is known to interact with components of the JNK pathway, so inhibiting JNK reduces HOP-1's functional contribution. | ||||||
IWR-1-endo | 1127442-82-3 | sc-295215 sc-295215A | 5 mg 10 mg | $82.00 $132.00 | 19 | |
Wnt pathway inhibitor that stabilizes Axin, causing degradation of β-catenin. HOP-1 is a downstream effector of β-catenin; its inhibition is a direct result of reduced β-catenin. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $153.00 $520.00 | 4 | |
GSK-3β inhibitor; increases β-catenin by blocking its degradation. HOP-1, a downstream effector, is inhibited by the accumulation of β-catenin. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
CDK inhibitor that prevents cell cycle progression. HOP-1 is implicated in the cell cycle, and its function is dampened when the cell cycle is halted. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
TGF-β inhibitor that prevents Smad2/3 phosphorylation. HOP-1 is known to interact with Smad proteins, so inhibiting TGF-β pathway affects HOP-1's ability to function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor; dampens the MAPK pathway. HOP-1 is indirectly regulated by the MAPK pathway via other interacting proteins, leading to its inhibition. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $46.00 | 2 | |
RAF kinase inhibitor disrupting the MAPK pathway. HOP-1 interacts with components of the MAPK pathway, so its function is reduced when RAF kinase is inhibited. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor; disrupts the PI3K/AKT pathway. As HOP-1 is regulated by PI3K/AKT pathway, its function is hindered by the inhibition of this pathway. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
JAK inhibitor; blocks JAK-STAT signaling. HOP-1 has known interactions with STAT proteins, so its activity is attenuated by JAK inhibition. | ||||||